Search the Newsreel

CNBC ‘Final Trades’: Netflix, AbbVie, Cerebras Systems - Netflix (NASDAQ:NFLX), CrowdStrike Holdings (NAS

This article summarizes the "Final Trades" segment on CNBC, highlighting stock picks from various financial experts. Recommendations include AbbVie (ABBV) with a raised price target, Transocean (RIG) ahead of earnings, Cerebras Systems (CBRS) due to a new cybersecurity partnership with CrowdStrike (CRWD), and Netflix …

ABT|Abbott Laboratories|Price:107.810|Chg%:-0.150

ABBV|AbbVie Inc|Price:256.910|Chg%:+3.610

AbbVie Inc. (ABBV) shows stable fundamentals and high growth potential, with its valuation considered fairly valued within the Pharmaceuticals industry. The stock is a high dividend payer and exhibits high institutional ownership. While the stock price is expected to trend upwards in the medium …

Abbott Laboratories stock trades steady as diagnostics and medical devices support earnings momentum

Abbott Laboratories' stock (ABT) is trading steadily, supported by diversified revenue streams from diagnostics, medical devices, nutrition, and established pharmaceuticals. Despite a decline in COVID-19 testing revenue, core businesses like continuous glucose monitoring and cardiovascular devices are driving growth, leading to resilient earnings and …

Genmab, AbbVie Clarify Epcoritamab Phase 3 Trial Missed Primary Endpoint

Genmab and AbbVie issued a clarification regarding their Phase 3 EPCORE DLBCL-1 trial, stating that overall survival was the sole U.S. primary endpoint and it was not met. This clarification was deemed necessary due to interpretive ambiguity in earlier disclosures, highlighting the complexities of …

Genmab, AbbVie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

Genmab and AbbVie announced that their lymphoma drug, epcoritamab, did not meet the primary endpoint in a Phase 3 clinical trial. The trial aimed to evaluate the drug's efficacy in patients with diffuse large B-cell lymphoma (DLBCL). This outcome is a setback for the …

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie clarified that overall survival (OS) was the sole U.S. primary endpoint for the Phase 3 EPCORE DLBCL-1 trial, which unfortunately did not meet this endpoint, indicating no statistically significant improvement in OS. The study evaluated epcoritamab in adults with relapsed or …

Epcoritamab U.S. Lymphoma Trial Does Not Meet Survival Endpoint

Genmab and AbbVie announced that their Phase 3 EPCORE® DLBCL-1 trial, evaluating epcoritamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival in the U.S. market. While epcoritamab is already approved under accelerated pathways for similar conditions, …

Abbott Stock And 2 Dividend Ideas For Retirement Income

This article explores three dividend stocks—Abbott Laboratories (ABT), Yü Group (AIM:YU.), and Artesian Resources (ARTN.A)—as potential retirement income sources, especially in light of Social Security reform concerns. It analyzes each company's overview, operations, market cap, and investment considerations, highlighting their strengths and risks for …

AbbVie: Bright Future, But Already Priced In (NYSE:ABBV)

AbbVie Inc. is rated a 'Hold' due to its slight overvaluation and high debt levels, despite strong Q1/26 revenue and free cash flow growth. The company's growth is largely driven by Skyrizi and Rinvoq, with pipeline diversification coming from Neuroscience and the Apogee Therapeutics …

Abbott Faces Joint Spinal Cord Stimulator Lawsuit Filed by 17 Patients

Seventeen patients have filed a joint product liability lawsuit against Abbott Laboratories, alleging that its spinal cord stimulator (SCS) systems were defective, failed to alleviate chronic pain, and caused painful neurological complications. The lawsuit claims that Abbott misrepresented the safety and approval status of …

Receita da Abbott atinge US$ 12,59 bilhões no 2T2026

Daiwa Securities Adjusts Price Target on Abbott Laboratories to $103 From $92, Maintains Neutral Rating

Daiwa Securities has adjusted its price target for Abbott Laboratories (ABT) to $103 from $92, while maintaining a Neutral rating on the stock. This adjustment comes amidst other analyst revisions for Abbott Laboratories, with several firms raising their price targets and maintaining positive ratings. …

Abbott Laboratories (ABT) Is Up 12.7% After Revenue Rises But Earnings Shrink In Q2 2026

Abbott Laboratories reported increased sales in Q2 2026 and for the first half of the year, but experienced a significant drop in net income and diluted earnings per share. This performance raises questions about cost pressures and profitability, leading to a focus on cost …

Abbott Laboratories (ABT) Earnings Drew Fresh Attention, Is It Still Below Fair Value?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Abbott Laboratories earnings put recent stock moves in context Abbott Laboratories (ABT) is back in focus after its latest quarterly earnings, where higher year over …

Abbott Laboratories Aktie: Umsatz auf 12,593 Milliarden

ABB India Shares Gain 2.12 percent to Rs 7,665.50; Board meeting scheduled for July 31,2026

ABB (SWX:ABBN) Stock Looks Above Fair Value After A 182% Run

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ABB stock has delivered a strong 182.3% total return over the past 5 years, yet the latest valuation checks suggest investors may now be …

AbbVie Inc. stock underperforms Wednesday when compared to competitors

AbbVie Inc. (ABBV) shares fell 1.09% on Wednesday, closing at $253.30, and underperformed the broader market, with both the S&P 500 and Dow Jones Industrial Average also seeing slight declines. The stock is currently 3.19% below its 52-week high reached earlier in July.

Total equity of AbbVie, Inc. – BCS:ABBV0

This article provides the total equity information for AbbVie, Inc. (BCS:ABBV0) from the Santiago Stock Exchange, accessed via TradingView. It indicates that the market was closed at the time of viewing and no trades were recorded. The content is primarily a data page with …

AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs

AbbVie Inc. and its Allergan Inc. unit have filed a patent infringement lawsuit against Galderma Group AG and Galderma SA. The lawsuit alleges that Galderma created dermal filler syringes for its Restylane product with a design similar to AbbVie's Juvéderm syringes, infringing on several …

Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?

AbbVie's oncology franchise is facing continued pressure, primarily due to declining Imbruvica sales, despite growth from newer therapies. The Zacks Consensus Estimate for Q2 oncology revenues suggests a slight decline from the previous year. The company's stock has outperformed the industry year-to-date, and it …

Canaccord raises Abbvie stock price target to $282 on growth outlook

Canaccord Genuity increased its stock price target for Abbvie Inc. (NYSE: ABBV) to $282 from $273, maintaining a Buy rating due to strong growth prospects. The firm anticipates a solid second quarter driven by prescription trends and the strategic $10 billion acquisition of APGE, …

ABBV Maintains Buy Rating -- Price Target Raised to $282 by Cana

Canaccord Genuity maintained a Buy rating for AbbVie (ABBV) and raised its price target from $273.00 to $282.00, reflecting confidence in the company's future performance. Despite the positive analyst outlook, GuruFocus indicates that ABBV is currently 20.3% overvalued with a GF Value™ of $212.81 …

Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating

Canaccord Genuity has increased its price target for AbbVie (ABBV) to $282 from $273, while reiterating a "Buy" rating on the stock. This adjustment reflects an updated outlook by the analyst firm on the pharmaceutical company. AbbVie specializes in therapeutic drug research and development, …

ETFs Investing in AbbVie, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold AbbVie, Inc. stocks, providing key financial data for each. It includes details such as market value, weight of ABBV in the ETF, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, …

Abbott (ABT) Stock May Be 32% Undervalued As Legal Overhang Fades

Abbott Laboratories (ABT) stock appears undervalued by roughly 32% according to Discounted Cash Flow (DCF) analysis and a tailored P/E ratio, despite trading at a premium to some industry averages. The valuation considers the company's shift towards higher-margin MedTech and diagnostics, including cancer and …

Abbott: EPS-Prognose auf 5,45–5,60 Dollar erhöht

How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin

In July 2026, Allergan Aesthetics, an AbbVie company, received European Commission approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration botulinum neurotoxin serotype E for adults with psychologically impactful moderate to severe glabellar lines, following similar approval in Canada. As the first approved serotype E neurotoxin …

EBIT per share of AbbVie, Inc. – BCS:ABBVCL1

This article provides financial information for AbbVie, Inc. under the ticker ABBVCL1 on the Santiago Stock Exchange, specifically focusing on its EBIT per share. It indicates that the market is currently closed with no trades. The content is primarily a data page from TradingView, …

AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know

AbbVie (ABBV) stock closed up 1.11% in its latest trading session, outperforming the S&P 500 and the Medical sector over the past month. The company is set to release its Q2 earnings on July 31, 2026, with analysts predicting significant growth in EPS and …

Patients sue diagnostics company over data breach

A class action lawsuit has been filed against Abbott Laboratories and its subsidiary Exact Sciences by Illinois patients, alleging the companies failed to adequately protect their sensitive data from a ransomware attack. The breach, for which the cybercriminal group ShinyHunters claimed responsibility, reportedly compromised …

Enterprise value of AbbVie, Inc. – BCS:ABBV0

This article from TradingView is a placeholder page for the enterprise value of AbbVie, Inc. (BCS:ABBV0) on the Santiago Stock Exchange. It provides market data, financial links, and community features, but lacks specific valuation data. The page indicates that the market is closed and …

AbbVie Stock Zigs When The Market Zags

AbbVie (ABBV) stock has shown a counter-cyclical pattern, rising even as the broader market declines, with a low correlation to the S&P 500. This is attributed to its strong business fundamentals, including growth in immunology drugs like Skyrizi and Rinvoq, and recent positive Phase …

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this maker of infant formula, medical devices …

AbbVie stock advances on a strong 2025 base

AbbVie Inc. stock is supported by its 2025 revenue of $56.33 billion and adjusted diluted EPS of $4.85, along with a quarterly dividend of $1.64 per share. The company's 2024 net revenue of $57.0 billion, a 3.7% increase from 2023, provides a strong comparison …